Eligibility for alirocumab or evolocumab treatment in 1090 hypercholesterolemic patients referred to a regional cholesterol treatment center with LDL cholesterol >= 70 mg/dL despite maximal-tolerated LDL-cholesterol-lowering therapy

Jetty, V; Glueck, CJ; Lee, K; Goldenberg, N; Prince, M; Kumar, A; Goldenberg, M; Anand, I; Wang, P

Jetty, V (reprint author), Jewish Hosp Cincinnati, Internal Med Dept, 4777 E Galbraith Rd, Cincinnati, OH 45236 USA.

VASCULAR HEALTH AND RISK MANAGEMENT, 2017; 13 ( ): 247

Abstract

Background: Proprotein convertase subtilisin/kexin type 9 inhibitors, Praluent (alirocumab [ALI]) and Repatha (evolocumab [EVO]) have been approved as......

Full Text Link


Links

期刊讨论 | 中国SCI论文 | 期刊主页 | 投稿经验 | 杂志官网 | 投稿链接 | 作者需知 | PMC链接 | Pubmed全文检索